924.5500 6.70 (0.73%)
NSE Jul 17, 2025 10:04 AM
Volume: 80,077
 

924.55
0.73%
Axis Direct
Q1 revenue growth (10% YoY) was in line, but EBITDA declined 34% YoY (37% below our expectations) on lower gross margin of 50.2% (down 260 bps YoY). Gross margin declined due to (1) price erosion in key partnership products in US; delay in its key approvals
Number of FII/FPI investors decreased from 283 to 268 in Mar 2025 qtr
More from Strides Pharma Science Ltd.
Recommended